Aixial is a global Contract Research Organization (CRO) with extensive expertise in providing high-quality clinical development services to the pharmaceutical and biotechnology industries.
Aixial’s experienced team excels in managing complex clinical studies across multiple therapeutic areas, including oncology, CNS, rare diseases, radiopharmaceutical and cell & gene therapy. With a strong focus on collaboration, providing tailored and efficient solutions, Aixial supports every phase of the drug development lifecycle, from early-stage clinical trials to post-market surveillance.
Aixial Group have been supporting complex radiopharmaceutical trials on a global scale for over 10 years for radiotherapeutic, radiodiagnostic as well as radiotheranostic investigational products. Aixial Group has successfully managed 32 radiopharmaceutical trials in a variety of indications, 22 of these in oncology, involving numerous radioisotopes in early Phase I/FIH, phase II and Phase III. Our focus is to make sure sponsors are comfortable and confident from the start, aware of potential risks in these complex studies, and realistic about results.
Aixial’s commitment, expertise and flexibility enhances the success rate of clinical trials for clients worldwide, making Aixial the CRO partner of choice.
Products